Clinical trials
Resistance clinical trials
Below are recruiting resistance clinical trials, each written for real people, not researchers. We’re tracking 1,207 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07344727Recruiting
Can haskap berries help you recover after heavy squats?
This study tests whether taking haskap berries (a type of superfruit) before and after intense squat workouts can speed up your recovery and reduce soreness.
Bozeman, MontanaAges 18–35 - NCT07127575Recruiting
Stress management study for college students
This trial tests a stress management program for college students. You will learn stress-reducing skills and use a heart rate monitor to see how your body responds.
West Lafayette, IndianaAges 18–30 - NCT07164443RecruitingPhase 3
Study comparing pasritamig to placebo for advanced prostate cancer
This trial tests a new drug called pasritamig against a placebo for people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. The goal is to see if pasritamig can help slow the cancer's growth.
La Jolla, CaliforniaAges 18 years+ - NCT07744334Recruiting
Exercise program for quarry workers with breathing problems
This study tests whether a program of aerobic and resistance exercises can help male quarry workers who have breathing problems caused by dust. The exercises may improve their lung function and overall fitness.
Minya, Minya GovernorateAges 30–40 - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06801236RecruitingPhase 1
A new drug for advanced prostate cancer that has stopped responding to treatment
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07716098RecruitingPhase 3
Esketamine nasal spray for treatment-resistant depression
This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.
Skokie, IllinoisAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Chandler, ArizonaAges 18 years+ - NCT07737990Enrolling by invitation
Psilocybin group therapy for treatment-resistant depression
This trial tests whether psilocybin-assisted group therapy can help people whose depression hasn't improved with other treatments. You must have already completed a prior psilocybin study to join this group.
Toronto, OntarioAges 18 years+ - NCT07184619RecruitingPhase 3
Evenamide for hard-to-treat schizophrenia (add-on study)
This trial tests a new medication, evenamide, added to your current antipsychotic treatment. It looks to see if it can help people whose schizophrenia has not responded well to standard therapies.
Los Angeles, CaliforniaAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Tucson, ArizonaAges 18 years+ - NCT07211438RecruitingPhase 2
Psilocybin with Monitors for Treatment-Resistant Depression
This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.
Toronto, OntarioAges 18–70 - NCT07726030Recruiting
Exercises for chronic rotator cuff pain in overhead athletes
This trial compares two types of exercises to see which better reduces chronic shoulder pain in male athletes who play overhead sports. If you have ongoing rotator cuff tendinopathy and are an active overhead athlete, this study may help find the best exercise approach for you.
Faisalābad, Punjab ProvinceAges 17–35 - NCT07563868Recruiting
Coaching to help ketamine therapy for hard-to-treat depression
This study tests whether adding coaching sessions can help people who are already getting ketamine or esketamine treatment for depression that hasn't responded to other medications. You'd receive weekly coaching calls designed to support your recovery while you continue your regular ketamine clinic visits.
Boston, MassachusettsAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Tucson, ArizonaAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Birmingham, AlabamaAges 18 years+ - NCT07717268RecruitingPhase 2
Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Zaragoza, AragonAges Any age - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT07677254Recruiting
Real world study of prostate cancer treatments
This study looks at real-world data from men with metastatic castration-resistant prostate cancer (mCRPC) to understand what treatments they receive and how they do. It may help doctors learn more about which treatments work best.
East Hanover, New JerseyAges 18–115 - NCT03272698RecruitingPhase 4
Ketamine plus ECT versus higher-dose ketamine with rescue
This study compares two ways of using ketamine with ECT (electroconvulsive therapy) in people with treatment-resistant depression. It aims to find whether a higher-dose ketamine approach, with extra rescue measures, works better or more safely.
Saskatoon, SaskatchewanAges 18 years+ - NCT03522545RecruitingPhase 1
Stem cell add-on for hard-to-treat bipolar depression
This Phase 1 study tests whether adding allogeneic (donor) stem cells to standard care is safe and may help adults with bipolar depression that has not improved with usual treatments. It mainly targets people with more severe symptoms and certain blood inflammation levels.
Houston, TexasAges 18–65 - NCT03537794Recruiting
Brain scan study in depression using a dopamine binding marker
This study uses a special brain imaging scan (PET) to measure how dopamine receptors are binding in people with treatment-resistant depression, compared with healthy volunteers. It aims to better understand brain chemistry differences that may help guide future treatment.
Toronto, OntarioAges 25–55
Hear when a new Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistance?
- Yes. Clin2 currently lists 1,207 recruiting resistance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.